Amgen’s Lumakras became the first FDA-approved drug that addresses the elusive KRAS mutation, but Mirati believes its newly approved therapy, Krazati, could be better. The small molecule’s ...

Amgen Inc. cancer drug, Lumakras, is displayed in its packaging at Thousand Oaks, in California, United States September 10, 2022. Amgen/Handout via REUTERS Purchase Licensing Rights, opens new tab.

Early trial data on Amgen Inc's Lumakras was released on Tuesday by the World Conference on Lung Cancer (WCLC), but meeting organizers decided to hold until Aug. 7 results from a highly ...

LUMAKRAS Met Primary Endpoint of Progression-Free Survival, Demonstrating Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer Detailed Data to ...

With Lumakras the first drug specifically approved for KRAS-mutated cancer, Amgen is examining various combination options to expand its reach. But new data underline the difficulty in finding the ...

--Amgen today announced new combination study results from the Phase 1 b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy of LUMAKRAS™, the ...

Amgen on Thursday reported preliminary results from two clinical trials of its KRAS-blocking cancer drug Lumakras, which showed disappointing tumor response and more side effects.

THOUSAND OAKS, Calif., Aug. 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data ...

RELATED: Amgen’s up-and-coming KRAS inhibitor gets a name: Lumakras Amgen's drug candidate is nearing an approval as a second-line therapy for patients with KRAS G12C-mutated locally advanced or ...

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the ...

LUMAKRAS ® (sotorasib) Demonstrated Delayed Time to CNS Progression, Longer CNS PFS and Higher Intracranial ORR vs Docetaxel in Post-Hoc Analysis of Phase 3 CodeBreaK 200 Trial LUMAKRAS Shows ...

Amgen Inc's Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company said on Sunday.